Maruti Suzuki Announces Winners of 9th Accelerator Cohort
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
Maruti Suzuki India Limited has announced the winners of the 9th Cohort of its flagship Accelerator program. This year's winners include six Indian startups — Frinks AI, mistEO, Adagrad, Com Olho, ProSolvr, and Eligere, along with three German startups — Caire AI, Syn2Core, and Talonic, under the newly introduced Global Startups category.
This is the first cohort to feature global participation, marking a key milestone in the program's journey. All nine winning startups will now engage in a proof of concept (PoC) with Maruti Suzuki, where they will test and validate their technologies in real-world conditions in collaboration with the company's teams.
Hisashi Takeuchi, Managing Director and CEO of Maruti Suzuki India Limited, said, "Startups bring fresh thinking and new ideas. Through the Maruti Suzuki Accelerator program, we have been working with them to co-create future-ready solutions that enhance customer experience and drive operational efficiency in the automobile manufacturing and mobility space."
"The participation of global startups, this cohort onwards, marks a new milestone in this journey. It further supports our efforts to contribute meaningfully to 'Make in India' and 'Startup India' initiatives of the Government. We welcome the winning startups to join us in our mission to offer 'Joy of Mobility' to as many people as possible," he added.
Out of 26 participating startups: 19 from India and 7 from Germany — the finalists showcased AI-driven innovations in fields like cybersecurity, EV infrastructure, road safety, and quality control. These solutions aim to boost operational efficiency and enhance the customer experience, aligning with Maruti Suzuki's long-term business growth plans.
Over the past six years, Maruti Suzuki claims to have screened over 5,000 startups, engaged with 150, and partnered with 25. The company runs multiple innovation initiatives, including the Maruti Suzuki Accelerator (launched in 2019), the Incubation Program (2020), the Mobility Challenge (2021), and the Nurture pre-incubation program (2023).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Is CEG Redefining Clean Energy With Customer-Focused Innovation?
Constellation Energy Corporation CEG is actively pursuing opportunities to develop, invest in, and bring to market innovative technologies that are critical to achieving a sustainable, low-carbon energy future. CEG aims to accelerate the transition away and enhance the reliability and resilience of the energy grid. These efforts reinforce its leadership position in the clean energy sector while also creating long-term value for customers, investors and the Energy designs specific plans for each customer, helping them reach their unique carbon reduction goals. The company offers a range of services, including energy efficiency upgrades, data-driven insights, and rebate and incentive programs, to help customers optimize their energy usage and reduce Energy offers innovative energy solutions, such as its 24/7 Carbon-Free Energy matching product, designed to help businesses meet their carbon reduction and sustainability goals more effectively. Additionally, CEG offers customers detailed, granular insights into their energy consumption through advanced data analytics and reporting Energy leverages advanced digital platforms, such as its proprietary Constellation Navigator. The Constellation Navigator platform provides businesses and organizations with a comprehensive suite of tools to monitor, analyze, and optimize their energy consumption across multiple sites and operations. Through this platform, customers can set and track decarbonization goals, and make informed decisions based on real-time focus on customer-driven innovation strengthens trust, enhances customer satisfaction, and positions Constellation Energy as a reliable, forward-thinking energy partner, ultimately driving long-term growth and value for both the company and its customers. Some other companies that are also focused on customer-centric solutions have been discussed below:Duke Energy DUK is actively leveraging innovation and customer-centric solutions to improve its operations and enhance the customer experience. This includes modernizing the energy grid, developing cleaner energy solutions and using technology to improve service delivery and customer Corporation PPL offers real-time usage tracking and predictive outage alerts. It utilizes smart grid technology and data analysis to provide customers with information about their energy consumption. In the past month, CEG's shares have risen 7.8% compared with the industry's 2.4% growth. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Constellation Energy's 2025 and 2026 earnings per share indicates an increase of 9% and 22%, respectively. Image Source: Zacks Investment Research CEG is trading at a premium relative to the industry, with a forward 12-month price-to-earnings of 29.7X compared with the industry average of 20.34X. Image Source: Zacks Investment Research CEG currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PPL Corporation (PPL) : Free Stock Analysis Report Constellation Energy Corporation (CEG) : Free Stock Analysis Report Duke Energy Corporation (DUK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Versailles Hospital Center adopts digital pathology platform
The Versailles Hospital Center has begun a digital pathology transformation by selecting Tribun Health's CaloPix imaging platform. This move is a significant step in modernising the French public healthcare system's diagnostic services and integrating artificial intelligence (AI) into pathology. The implementation of CaloPix within the pathology department is set to streamline primary diagnostics and interdisciplinary collaboration. Tribun Health CEO Jean-François POMEROL said: 'This choice reflects a shared commitment to innovating for more effective, collaborative, and patient-centered healthcare.' Tribun Health's platform has a user-friendly interface and flexibility, catering to the dynamic requirements of hospital infrastructures. It is designed to be open and interoperable, allowing it to integrate with the hospital's digital strategy. This initiative is in line with the Versailles Hospital Center and GHT 78 Sud's digital objectives, which are coordinated with GHT Nord. It contributes to a national effort to upgrade and digitise healthcare facilities. Versailles Hospital Center is GHT 78 Sud's supporting institution. Versailles Hospital Center Pathology Department head Dr Claire GLASER said: 'The selection of CaloPix is fully aligned with our digital transformation strategy. We were impressed by the solution's user-friendliness, performance, and the quality of support offered by Tribun Health's teams. 'This project, developed in collaboration with the GHT Yvelines Nord, marks a key step for the future of our specialty in the region, particularly regarding AI and collaborative work. It also enhances our integration into APHP's expert networks equipped with the same software.' Tribun Health uses data-driven technology and AI to improve precision and minimise turnaround times to assist laboratories and hospitals in transitioning from glass slide pathology to complete digital solutions. "Versailles Hospital Center adopts digital pathology platform" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
35 minutes ago
- Yahoo
Modella AI and AstraZeneca link for cancer clinical development
Modella AI has signed a multi-year agreement with AstraZeneca to expedite AI-driven oncology clinical development. The partnership will give AstraZeneca access to Modella AI's multi-modal foundation models. The agreement will enable the use of Modella AI's latest models, with rich feature extraction from different types of data, to speed up clinical development across AstraZeneca's worldwide oncology portfolio. AstraZeneca oncology research and development (R&D) chief AI and data scientist Jorge Reis-Filho stated: 'At AstraZeneca, AI is integrated across every aspect of clinical development. 'Through the use of foundation models, combined with our unique datasets and AI expertise, we are confident in our strategy to accelerate development and increase the probabilities of success in our oncology clinical trials.' AstraZeneca will use Modella AI's platform for cancer research R&D capabilities to improve biomarker discovery and clinical development while enhancing patient outcomes. By integrating these advanced foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods with increased speed. Modella AI CEO Jill Stefanelli stated: 'Foundation models are transforming precision medicine. They are the backbone of AI-powered biomedical discovery and mark the first step toward fully autonomous AI agents. 'Our state-of-the-art multimodal foundation models provide powerful features from different data types for downstream tasks. When integrated with AstraZeneca's research engine, they will have the potential to accelerate data-driven development and enable the development of new AI agents that can automate complex R&D workflows.' In June 2025, the US Food and Drug Administration (FDA) approved AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that exhibits mutations in the epidermal growth factor receptor. "Modella AI and AstraZeneca link for cancer clinical development" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
